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QUESTIONS
1. What is bullous pemphigoid (BP)?
2. How does disease occur in BP?
3. How did the investigators carry out their study, and what did they find?
4. What were the investigators’ conclusions?
Most dermatologists encounter patients with bullous pemphi-
goid (BP); however, many key questions about this disease remain 
unanswered. Why does someone get BP? Why do some patients 
with BP have a single episode followed by disease resolution, 
whereas in other patients the disease persists for a considerable 
time? In addition, why does one individual with BP have a mild 
course while another has extensive disease with severe symp-
toms? The study by Di Zenzo and co-workers in this issue helps to 
shed light on the latter question.
Antibodies aimed at the BP180 antigen of type XVII collagen are 
important in the pathogenesis of BP (Nishie et al., 2007). In mice 
engineered to express the human BP180 protein in place of the 
mouse homolog of BP180, injection of antihuman BP180 anti-
bodies causes the development of bullae that clinically and his-
tologically resemble those found in BP. Specifically, an epitope 
(a portion of the protein) of the extracellular domain of BP180 
known as BP180-NC16A is thought to be critical for this disease. 
Over time, additional epitopes may be targeted by autoantibod-
ies, a phenomenon termed epitope spreading (ES). ES may represent either an epiphenomenon of an autoimmune 
disease or an important part of the disease pathogenesis itself.
Previously, Di Zenzo et al. (2008) demonstrated that BP patients may have antibodies against many epitopes of 
BP180 and BP230. In the study reported in this issue of the Journal, Di Zenzo et al. (2011) tested the hypothesis that ES 
might be important in disease progression and severity by studying ES in 35 patients with BP over a 12-month period. 
ES occurred in nearly half of the patients (17), occurred early in the disease process, and was related to disease sever-
ity at the time of diagnosis. Among patients with ES, IgG reactivity to extracellular epitopes of BP180 and intracel-
lular epitopes of BP230 (a secondary BP antigen) was correlated with disease severity. These results lend support to 
the concept that ES, especially early in disease, may influence an individual’s course of BP. Through the following 
questions, we examine this paper in greater detail. For brief answers, please refer to the supplementary information 
online <http://www.nature.com/jid/journal/v131/n11/suppinfo/jid2011309s1.html>.
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